Latest news with #ALCAR
Yahoo
3 days ago
- Business
- Yahoo
CARMAT Announces Filing Today for Insolvency and Requesting Being Placed in Receivership
Suspension of CARMAT shares trading starting June 30, 2025, before stock market opening PARIS, June 30, 2025--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announces filing for insolvency1 and requesting to be placed in receivership2 to the Versailles Economic Affairs Court3, as well as the suspension of CARMAT shares trading, starting June 30, 2025, before stock market opening. Insolvency filing and request to be placed in receivership On June 20, 2025, CARMAT announced in a press release being at risk of insolvency as early as the end of June 2025 unless managing before then, to secure additional cash of at least €3.5 million. Despite its continued efforts, the Company has not managed at this stage, to secure neither additional cash nor new financing. Given this, the Company will today file for insolvency and request to be placed in receivership to the Versailles Economic Affairs Court ("the Court"). The Court will rule on this request, following a hearing expected in the coming days. As a reminder, according to its current business plan and assuming "business as usual" situation, the Company estimates its funding requirements over the next 12 months at approximately €35 million, including approximately €20 million by the end of December 2025. Suspension of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR) Pending the Court's decision, CARMAT has asked Euronext to suspend the trading of its shares starting on June 30, 2025, before the stock market opens. The Company anticipates this suspension to be lifted once the Court's decision has been rendered and communicated to the market. Next steps Pending the Court's decision, CARMATS's operations carry-on and the Company continues to actively explore all options to ensure the continuation of its business activities. The Company believes that the opening of a receivership procedure would be the most appropriate framework to facilitate this continuation. More generally, whatever the Court's decision, the Company will endeavor to provide continuous support to patients who currently benefit from its Aeson® artificial heart. Press releases will be issued regularly as the Company's situation evolves and the proceedings progress. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company's ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Name: CARMATISIN code: FR0010907956Ticker: ALCAR Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the "AMF") under number D.25-0345 (the "2024 Universal Registration Document"), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway extends only until the end of June 2025, and that CARMAT is therefore facing a very high risk of default, including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA). 1 « Déclaration de cessation des paiements » 2 « Redressement judiciaire » 3 « Tribunal des Affaires Economiques de Versailles » View source version on Contacts CARMAT Stéphane Piat Chief Executive Officer Pascale d'Arbonneau Deputy Chief Executive Officer & Chief Financial OfficerTel.: +33 1 39 45 64 50contact@ NewCap Press Relations Nicolas Merigeau Arthur Rouillé Tel.: +33 1 44 71 94 98carmat@ NewCap Financial Communication& Investor Relations Dusan Oresansky Jérémy Digel Tel.: +33 1 44 71 94 92carmat@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
3 days ago
- Business
- Reuters
France's Carmat files for insolvency, shares suspended
June 30 (Reuters) - French heart prosthesis company Carmat ( opens new tab has filed for insolvency and requested to be placed in receivership after failing to secure emergency funding, it said on Monday. Trading in Carmat shares has been suspended from Monday before market open at the company's request, pending a decision from the court, the group added.
NDTV
30-04-2025
- Health
- NDTV
These Supplements Can Help Reduce Brain Fog
Brain fog is a non-medical term used to describe a state of mental fatigue or clouded thinking, where a person may struggle with concentration, memory, mental clarity, and alertness. It can feel like mental sluggishness or being 'spaced out.' Causes of brain fog range from stress, poor diet, lack of sleep, hormonal imbalances, and sedentary lifestyle, to underlying conditions like hypothyroidism, inflammation, or nutrient deficiencies. Supplements can help reduce brain fog when it's linked to nutritional gaps, chronic inflammation, oxidative stress, or neurotransmitter imbalances. Keep reading as we list supplements you can add to your diet to reduce brain fog. 7 Supplements that can help reduce brain fog 1. Omega-3 fatty acids Omega-3s are essential fats found in fish oil that support brain structure and function. DHA, in particular, makes up a large portion of the brain's grey matter. These fats reduce inflammation, improve communication between brain cells, and are known to enhance memory and mood. People deficient in omega-3s often report mental fatigue, so supplementation can help restore clarity and focus. 2. Vitamin B12 Vitamin B12 is vital for energy production and nerve health. A deficiency can lead to fatigue, memory issues, and confusion, all classic symptoms of brain fog. Supplementing with B12 supports the production of neurotransmitters like serotonin and dopamine and helps maintain the protective sheath around nerves (myelin), which is essential for fast and clear communication between brain cells. 3. L-Theanine Found naturally in green tea, L-theanine promotes relaxation without sedation. It helps calm the mind, improve focus, and reduce mental clutter. When combined with caffeine, L-theanine can enhance attention and working memory while minimising the jitteriness caffeine sometimes causes. This makes it especially useful for managing stress-induced brain fog. 4. Ginkgo biloba Ginkgo biloba enhances blood circulation to the brain, which helps deliver more oxygen and nutrients to brain tissues. This improved flow supports better concentration, mental sharpness, and memory retention. Ginkgo also has antioxidant properties that protect brain cells from oxidative stress, which is a key contributor to cognitive decline and fogginess. 5. Magnesium Magnesium plays a role in over 300 enzymatic processes, including those related to brain and nervous system function. Low levels of magnesium can lead to irritability, anxiety, and poor concentration. Magnesium supplements, particularly magnesium threonate, have been shown to support synaptic plasticity and memory, helping clear brain fog caused by stress and sleep issues. 6. ALCAR Acetyl-L-Carnitine also known as ALCAR supports energy production in brain cells by transporting fatty acids into mitochondria. It also helps produce acetylcholine, a key neurotransmitter involved in learning and memory. ALCAR has been shown to improve mental energy, clarity, and alertness, particularly in people experiencing fatigue or age-related cognitive decline. 7. Vitamin D Vitamin D plays a role in regulating mood, reducing inflammation, and supporting immune and brain health. Deficiency is often linked to depression, fatigue, and cognitive issues. Supplementing with vitamin D, especially in those who get little sunlight, can help lift brain fog by enhancing mood-regulating chemicals and reducing inflammatory responses in the brain. Supplements work by supporting brain function, improving blood flow, reducing inflammation, and enhancing the production of essential brain chemicals. Add them to your routine today to boost health. Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.
